Faraday Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for preventing and treating cardiac and skeletal muscle loss. Its lead program, FDY-5301, aims to mitigate reperfusion damage during cardiac interventions, addressing critical needs in cardiovascular medicine.
California, • United States
Florida, • United States
New York, • United States
New Jersey, • United States
California, • United States
Florida, • United States
British Columbia, • Canada
Greater London, • United Kingdom